Gore reports that more than 2,500 patients have been enrolled in the Gore global registry for endovascular aortic treatment (GREAT). The registry is part of Gore’s dedication to post-market surveillance and monitoring long-term device performance in an effort to improve clinical practice and patient outcomes.
Since August 2010, GREAT has collected data on patients treated with the minimally invasive Gore Tag thoracic endoprosthesis, conformable Gore Tag thoracic endoprosthesis, Gore excluder AAA endoprosthesis, Gore Excluder AAA endoprosthesis featuring C3 delivery system and most recently, the Gore Excluder iliac branch endoprosthesis. A total of 5,000 consecutive patients from up to 300 worldwide sites will be enrolled in the registry and their treatment results will be tracked for 10 years.
“What separates the Gore registry from other medical registries is the minimal exclusion criteria, unprecedented number of patients, and length of follow-up,” said Ross Milner, professor of surgery, co-director, Center for Aortic Diseases, and associate programme director, Vascular Surgery Fellowship at the University of Chicago Medical Center. “The active tracking of long-term device performance and associated patient outcomes will provide key insights into real-world clinical practice, which is vital to advancing the future of endovascular repair and improving patient outcomes.”
GREAT is currently comprised of 2,511 patients at 84 sites in 13 countries. The registry tracks outcomes during patient treatment and post-treatment visits for up to 10 years, providing longer-term follow-up than past prospective registries. In addition to procedural and clinical outcomes, data collected include device used, treatment indication, patient demographics, and medical history.
“GREAT demonstrates the collaborative dedication of physicians around the world to advance patient care,” said Piergiorgio Cao chief of vascular surgery at San Camillo Forlanini Hospital, Rome, Italy. “We want to ensure that patients are receiving optimal treatment through safe therapies.”
To date, 80% of the GREAT procedures have been endovascular aneurysm repair, 16% thoracic endovascular aortic repair, and 4% were other endovascular procedures. The most commonly treated pathologies have been abdominal aortic aneurysm (72%), iliac aneurysms (10%), descending thoracic aortic aneurysms (7%), and type B dissections (3%).
GREAT investigators have consistently shared registry results through publication and presentations at professional and society meetings. The latest registry findings and outcomes will be presented at the 2015 Charing Cross International Symposium in April and Vascular Annual Meeting in June.
